On this page
MedPlus pauses ₹100 crore concierge healthcare pilot, keeps 800-store FY27 plan
Our read
MedPlus is likely to trade near-term healthcare-services optionality for a more investor-palatable pharmacy-led growth push, with the FY27 store rollout becoming the primary test of its capital discipline.
For operators
MedPlus is prioritizing scalable pharmacy-store expansion over a higher-complexity concierge healthcare pilot, keeping its FY27 target of 800 new outlets intact.
Watch
Board decision and any revised budget or timeline for the concierge healthcare proposal.
The report,
MedPlus paused its proposed concierge healthcare and wellness pilot after investor feedback, pending board review. The Hyderabad-based pharmacy retailer continues aggressive expansion, with 5,476 stores as of June 30, 2026, and plans to add 800 outlets in FY27.
Reported figures
From the report. Source details below
| 663 stores added in past | 12 months |
|---|
Also in the report
- ₹115 crore proposed investment
- More than 20% stock decline over past year
- 146 stores added in April-June quarter
- ₹8,421.61 crore market capitalisation
Other figures
- ₹701.90 NSE share price
Why it matters to operators
With concierge healthcare deferred pending board review, MedPlus may be more selective about healthcare-service partnerships and favor opportunities that strengthen its pharmacy network economics.
What to watch next
- Quarterly net store additions versus the 800-store FY27 target and evidence of new-store cannibalization.
- Same-store sales growth, EBITDA margin, inventory days and operating cash flow during the expansion cycle.
- Management commentary on store-level breakeven periods, lease costs and geographic mix of openings.
- Partnership announcements with diagnostics, telehealth, insurers or wellness providers.
- Investor reactions to capex, debt, free-cash-flow trends and any change in expansion guidance.
Likely next moves
Our read of what comes next — analysis, not reported by the source.
- Reallocate concierge-pilot budget toward store openings, supply-chain capacity, working capital and pharmacy automation.
- Present a clearer board-approved capital-allocation framework, including store payback thresholds and return hurdles for non-pharmacy adjacencies.
- Concentrate new stores in underserved clusters to improve delivery coverage, procurement leverage and brand visibility.
- Test wellness, diagnostics and consultation offerings through asset-light partnerships before committing to owned-service infrastructure.
- Use the larger network to expand private-label, chronic-care subscriptions and omnichannel refill programs.
The counter-case
The case against this reading — not reported by the source.
Pausing a ₹100 crore adjacency after investor pushback may signal weak strategic discipline or limited confidence in MedPlus’s ability to monetize healthcare services beyond dispensing. Keeping an aggressive 800-store FY27 expansion target could compound the issue: rapid rollout risks lower-quality locations, cannibalization, rising fixed costs and weaker payback periods if pharmacy demand or same-store growth slows. A larger footprint also does not solve structural pressure from discounting, e-pharmacies, quick-commerce medicine delivery and margin-sensitive consumers.
The source
First seen